Total Payments
$9,100
2024 Payments
$1,043
Companies
16
Transactions
567
Medicare Patients
1,618
Medicare Billing
$136,396
Payment Breakdown by Category
Food & Beverage$8,623 (94.8%)
Education$476.60 (5.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,623 | 559 | 94.8% |
| Education | $476.60 | 8 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $2,175 | 94 | $0 (2024) |
| Alkermes, Inc. | $1,291 | 75 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,053 | 82 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $992.05 | 76 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $800.02 | 55 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $790.76 | 55 | $0 (2022) |
| ABBVIE INC. | $642.03 | 61 | $0 (2024) |
| ITI, Inc. | $469.87 | 14 | $0 (2023) |
| Allergan, Inc. | $281.68 | 27 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $213.55 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,043 | 59 | Neurocrine Biosciences, Inc. ($221.41) |
| 2023 | $1,639 | 92 | Janssen Pharmaceuticals, Inc ($571.46) |
| 2022 | $1,391 | 92 | ABBVIE INC. ($276.60) |
| 2021 | $1,182 | 94 | Janssen Pharmaceuticals, Inc ($199.71) |
| 2020 | $657.33 | 47 | Sunovion Pharmaceuticals Inc. ($175.97) |
| 2019 | $881.71 | 51 | Alkermes, Inc. ($228.47) |
| 2018 | $1,328 | 73 | Janssen Pharmaceuticals, Inc ($534.15) |
| 2017 | $977.67 | 59 | Otsuka America Pharmaceutical, Inc. ($230.02) |
All Payment Transactions
567 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: Neuroscience | ||||||
| 12/19/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $35.18 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $20.05 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/19/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: Central Nervous System | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $24.07 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/04/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Neuropsychiatry | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: Central Nervous System | ||||||
| 12/02/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.12 | General |
| Category: Neuropsychiatry | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $19.99 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/20/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $6.33 | General |
| Category: Central Nervous System | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $116.54 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/13/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: Neuropsychiatry | ||||||
| 11/06/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: CNS | ||||||
| 10/31/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $6.21 | General |
| Category: Neuropsychiatry | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.29 | General |
| 10/22/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Neuroscience | ||||||
| 10/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $12.92 | General |
| Category: Central Nervous System | ||||||
| 10/16/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $5.92 | General |
| Category: Neuropsychiatry | ||||||
| 10/16/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $0.38 | General |
| Category: Central Nervous System | ||||||
| 10/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: Neuropsychiatry | ||||||
| 09/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $19.65 | General |
| 09/18/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 329 | 839 | $90,164 | $35,566 |
| 2022 | 8 | 372 | 768 | $81,619 | $32,160 |
| 2021 | 7 | 485 | 1,179 | $98,414 | $37,374 |
| 2020 | 7 | 432 | 1,123 | $95,872 | $31,297 |
Total Patients
1,618
Total Services
3,909
Medicare Billing
$136,396
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 197 | $36,886 | $15,972 | 43.3% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 39 | 92 | $24,380 | $9,411 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 40 | 84 | $9,277 | $3,979 | 42.9% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2023 | 19 | 25 | $4,365 | $2,728 | 62.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 90 | 376 | $9,400 | $2,673 | 28.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 48 | 65 | $5,856 | $802.95 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 119 | $28,495 | $10,494 | 36.8% |
| 90837 | Psychotherapy, 1 hour | Office | 2022 | 30 | 47 | $12,455 | $5,407 | 43.4% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 40 | 50 | $8,099 | $5,280 | 65.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 63 | $7,840 | $3,489 | 44.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 104 | 342 | $8,550 | $2,829 | 33.1% |
| 90834 | Psychotherapy, 45 minutes | Office | 2022 | 29 | 36 | $6,300 | $2,444 | 38.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 65 | 92 | $8,208 | $1,219 | 14.8% |
| 90832 | Psychotherapy, 30 minutes | Office | 2022 | 19 | 19 | $1,672 | $997.71 | 59.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 70 | 112 | $27,975 | $9,091 | 32.5% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2021 | 57 | 74 | $10,235 | $6,992 | 68.3% |
| 90834 | Psychotherapy, 45 minutes | Office | 2021 | 46 | 87 | $15,225 | $6,773 | 44.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 55 | 95 | $12,192 | $5,263 | 43.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 126 | 611 | $15,275 | $4,852 | 31.8% |
| 90832 | Psychotherapy, 30 minutes | Office | 2021 | 26 | 43 | $3,784 | $2,243 | 59.3% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 105 | 157 | $13,728 | $2,160 | 15.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 81 | 160 | $40,702 | $11,563 | 28.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 120 | 603 | $15,075 | $5,673 | 37.6% |
| 90834 | Psychotherapy, 45 minutes | Office | 2020 | 26 | 57 | $9,975 | $4,038 | 40.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 81 | $10,690 | $4,019 | 37.6% |
About Dr. Kathleen Lundvall, MD
Dr. Kathleen Lundvall, MD is a Psychiatry healthcare provider based in Lexington, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1508919879.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kathleen Lundvall, MD has received a total of $9,100 in payments from pharmaceutical and medical device companies, with $1,043 received in 2024. These payments were reported across 567 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($8,623).
As a Medicare-enrolled provider, Lundvall has provided services to 1,618 Medicare beneficiaries, totaling 3,909 services with total Medicare billing of $136,396. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Lexington, SC
- Active Since 01/19/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1508919879
Products in Payments
- INVEGA SUSTENNA (Drug) $1,718
- INGREZZA (Drug) $972.08
- VRAYLAR (Drug) $923.71
- LATUDA (Drug) $790.76
- ARISTADA (Drug) $773.71
- ABILIFY MAINTENA (Drug) $547.82
- CAPLYTA (Drug) $491.22
- AUSTEDO (Drug) $439.36
- INVEGA TRINZA (Drug) $415.45
- Aristada 441 mg (Drug) $386.91
- REXULTI (Drug) $321.06
- COBENFY (Drug) $156.58
- Austedo XR (Drug) $133.10
- LYBALVI (Drug) $130.19
- UZEDY (Drug) $127.31
- Fanapt (Drug) $117.05
- HETLIOZ (Drug) $77.09
- SPRAVATO (Drug) $41.52
- PERSERIS (Drug) $29.89
- ABILIFY ASIMTUFII (Drug) $20.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Lexington
Mark Wright, M.d, M.D
Psychiatry — Payments: $619,046
Psychiatry $619,046
Dr. Steven Croley, Md, MD
Psychiatry — Payments: $111,876
Psychiatry $111,876
Syed Rizvi, M.d, M.D
Psychiatry — Payments: $17,719
Psychiatry $17,719
Dr. Paolo Cassano, Md, Phd, MD, PHD
Psychiatry — Payments: $12,649
Psychiatry $12,649
Dr. Getulio Tovar, M.d, M.D
Psychiatry — Payments: $9,055
Psychiatry $9,055
Mr. Saeed Hamid, M.d, M.D
Psychiatry — Payments: $8,148
Psychiatry $8,148